Replies to post #20 on Aligos Therapeutics Inc (ALGS)

[DewDiligence]

ALGS 1Q23 results—3/31/22 cash=$104M, down from $126M at 12/31/22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500905.html

ALGS expects to start a phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, in the UK in mid 2023.

No CC.